<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>23755944</identifier>
<setSpec>1579-2013</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>García-Seco, José Alberto</dc:author>
<dc:author>García-Seco, Fernando</dc:author>
<dc:author>Seco-Segura, Ángela María</dc:author>
<dc:author>Lozano-Serrano, Monserrat</dc:author>
<dc:author>Moreno-Fernández, Jesús</dc:author>
<dc:author>Sánchez-Covisa, Miguel Aguirre</dc:author>
<dc:author>Lozano-Hernández, María Concepción</dc:author>
<dc:author>Muñoz-Cazallas, Pedro Antonio</dc:author>
<dc:author>Ferreiro-Vicario, Carmen</dc:author>
<dc:description xml:lang="en">OBJECTIVE To assess the quality of life (QOL) and satisfaction (SF) in patients with type 1 diabetes mellitus (T1DM) treated with continuous subcutaneous insulin infusion (CSII) compared with multiple daily insulin injections (MDI). METHOD A descriptive study was conducted to assess the QOL and SF of 68 patients on CSII or MDI treatment (1:2). The instruments used were, the Spanish version of the Diabetes Quality of Life (EsDQOL) specific for diabetes related QOL, SF-36 for general QOL, and the Diabetes Treatment Satisfaction Questionnaire (DTSQ) for SF evaluation. RESULTS The EsDQOL scores for patients on CSII therapy were similar to those treated with MDI (87.20±21.11 vs 86.83±20.7, P=.86), with lower scores in the SF-36 questionnaire (66.91±15.76 vs 75.90±14.56, P=.03) except in Health Transition section, where patients treated with CSII showed higher scores (68.75±19.66 vs 57.93±17.18, p=.02). The values obtained in the DTSQ questionnaire were higher in CSII patients compared with the MDI group in last weeks (31.50±4.66 vs 27.83±6.06, p=.01) and last three months periods (13.2±6.73 vs 8.77±7.40, p=.01). CONCLUSIONS Patients with T1DM on CSII therapy showed a poorer global QOL, although they felt more satisfied with their treatment than those treated with MDI. No differences in diabetes related QOL were detected between groups.</dc:description>
<dc:type>Comparative Study</dc:type>
<dc:language>es</dc:language>
<dc:date>2013 May-Jun </dc:date>
<dc:title xml:lang="es">Valoración de la satisfación y calidad de vida en pacientes con diabetes mellitus tipo 1 en tratamiento con infusión subcutánea continua de insulina comparado con multidosis de insulina.</dc:title>
<dc:title xml:lang="en">[Satisfaction and quality of life evaluation in patients with type 1 diabetes mellitus treated using continuous subcutaneous insulin infusion compared with multiple daily injections].</dc:title>
<dc:publisher>Enfermeria clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
